JP2019515042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515042A5 JP2019515042A5 JP2019510574A JP2019510574A JP2019515042A5 JP 2019515042 A5 JP2019515042 A5 JP 2019515042A5 JP 2019510574 A JP2019510574 A JP 2019510574A JP 2019510574 A JP2019510574 A JP 2019510574A JP 2019515042 A5 JP2019515042 A5 JP 2019515042A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- compound
- independently
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021067440A JP2021107415A (ja) | 2016-05-05 | 2021-04-13 | 統合ストレス経路のモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332284P | 2016-05-05 | 2016-05-05 | |
| US62/332,284 | 2016-05-05 | ||
| PCT/US2017/031352 WO2017193030A1 (en) | 2016-05-05 | 2017-05-05 | Modulators of the integrated stress pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021067440A Division JP2021107415A (ja) | 2016-05-05 | 2021-04-13 | 統合ストレス経路のモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515042A JP2019515042A (ja) | 2019-06-06 |
| JP2019515042A5 true JP2019515042A5 (enExample) | 2020-06-25 |
| JP6869331B2 JP6869331B2 (ja) | 2021-05-12 |
Family
ID=58710114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510574A Expired - Fee Related JP6869331B2 (ja) | 2016-05-05 | 2017-05-05 | 統合ストレス経路のモジュレーター |
| JP2021067440A Pending JP2021107415A (ja) | 2016-05-05 | 2021-04-13 | 統合ストレス経路のモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021067440A Pending JP2021107415A (ja) | 2016-05-05 | 2021-04-13 | 統合ストレス経路のモジュレーター |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10864196B2 (enExample) |
| EP (2) | EP3452454B1 (enExample) |
| JP (2) | JP6869331B2 (enExample) |
| CN (1) | CN109641853A (enExample) |
| AR (1) | AR108394A1 (enExample) |
| AU (1) | AU2017260363B2 (enExample) |
| CA (1) | CA3023161A1 (enExample) |
| ES (1) | ES2821790T3 (enExample) |
| PT (1) | PT3452454T (enExample) |
| TW (1) | TW201808914A (enExample) |
| UY (1) | UY37231A (enExample) |
| WO (1) | WO2017193030A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| CN112713985B (zh) | 2017-05-05 | 2022-03-08 | 华为技术有限公司 | 传输信号的方法和装置 |
| MX389668B (es) * | 2017-05-15 | 2025-03-20 | Recurium Ip Holdings Llc | Compuestos biciclo[1.1.1]pentilo sustituidos y uso de los mismos para el tratamiento del dolor y fiebre. |
| JP2020522553A (ja) * | 2017-06-07 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化合物 |
| WO2018225093A1 (en) * | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CN111094233B (zh) | 2017-08-09 | 2024-03-15 | 戴纳立制药公司 | 化合物、组合物及方法 |
| PT3676297T (pt) | 2017-09-01 | 2023-08-29 | Denali Therapeutics Inc | Compostos, composições e métodos |
| AU2018360847B2 (en) * | 2017-11-02 | 2023-07-27 | Abbvie Inc. | Modulators of the integrated stress pathway |
| AU2018358157B2 (en) * | 2017-11-02 | 2023-03-09 | Abbvie Inc. | Modulators of the integrated stress pathway |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| US20200347033A1 (en) * | 2017-11-02 | 2020-11-05 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| RU2020122711A (ru) | 2017-12-13 | 2022-01-17 | ПРАКСИС БАЙОТЕК ЭлЭлСи | Ингибиторы пути интегрированной реакции на стресс |
| US20210130308A1 (en) * | 2018-03-23 | 2021-05-06 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| SG11202011014VA (en) | 2018-06-05 | 2020-12-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| CA3112326A1 (en) | 2018-09-12 | 2020-03-19 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| CA3129609A1 (en) * | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Eukaryotic initiation factor 2b modulators |
| AU2020261234A1 (en) * | 2019-04-23 | 2021-11-11 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| EA202192900A1 (ru) * | 2019-04-23 | 2022-03-18 | Эвотек Интернешнл Гмбх | Модуляторы пути интегрированной реакции на стресс |
| PH12021552759A1 (en) | 2019-04-30 | 2022-07-04 | Abbvie Inc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| CA3142748A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| WO2021061898A1 (en) | 2019-09-26 | 2021-04-01 | Novartis Ag | Antiviral pyrazolopyridinone compounds |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| CR20220325A (es) | 2019-12-20 | 2022-08-19 | Tenaya Therapeutics Inc | Fluoroalquil-oxadiazoles y sus usos |
| KR20220133252A (ko) | 2020-01-28 | 2022-10-04 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절자 |
| JP2023517944A (ja) * | 2020-03-11 | 2023-04-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
| AU2021366303A1 (en) | 2020-10-22 | 2023-06-22 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| CA3195290A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| CA3216768A1 (en) | 2021-05-04 | 2022-11-10 | Jin Yang | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| CN120187707A (zh) * | 2022-11-21 | 2025-06-20 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其合成方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212A (en) | 1847-07-31 | Richard m | ||
| US162A (en) | 1837-04-17 | Island | ||
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| CN100471854C (zh) * | 2002-12-20 | 2009-03-25 | 麦克公司 | 用作11-β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物 |
| JP2007517868A (ja) | 2004-01-07 | 2007-07-05 | アストラゼネカ アクチボラグ | 治療薬ｉ |
| US7217838B2 (en) | 2005-01-05 | 2007-05-15 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| CA2627722A1 (en) * | 2005-10-31 | 2007-06-21 | Merck & Co., Inc. | Cetp inhibitors |
| WO2011087758A1 (en) | 2009-12-22 | 2011-07-21 | H. Lundbeck A/S | Adamantyl amide derivatives and uses of same |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| AU2014233520B2 (en) * | 2013-03-15 | 2019-02-21 | The Regents Of The University Of California | Modulators of the eIF2alpha pathway |
| WO2015038778A1 (en) * | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
| US10526294B2 (en) * | 2016-06-24 | 2020-01-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
-
2017
- 2017-05-04 TW TW106114862A patent/TW201808914A/zh unknown
- 2017-05-05 UY UY0001037231A patent/UY37231A/es not_active Application Discontinuation
- 2017-05-05 ES ES17724205T patent/ES2821790T3/es active Active
- 2017-05-05 EP EP17724205.4A patent/EP3452454B1/en active Active
- 2017-05-05 AU AU2017260363A patent/AU2017260363B2/en not_active Expired - Fee Related
- 2017-05-05 US US16/098,950 patent/US10864196B2/en active Active
- 2017-05-05 JP JP2019510574A patent/JP6869331B2/ja not_active Expired - Fee Related
- 2017-05-05 CN CN201780042067.3A patent/CN109641853A/zh active Pending
- 2017-05-05 EP EP20184319.0A patent/EP3778575A1/en not_active Withdrawn
- 2017-05-05 CA CA3023161A patent/CA3023161A1/en not_active Abandoned
- 2017-05-05 AR ARP170101182A patent/AR108394A1/es unknown
- 2017-05-05 PT PT177242054T patent/PT3452454T/pt unknown
- 2017-05-05 WO PCT/US2017/031352 patent/WO2017193030A1/en not_active Ceased
-
2020
- 2020-05-28 US US16/885,766 patent/US20210113532A1/en not_active Abandoned
-
2021
- 2021-04-13 JP JP2021067440A patent/JP2021107415A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515042A5 (enExample) | ||
| JP2019519599A5 (enExample) | ||
| JP2019515043A5 (enExample) | ||
| JP2019530649A5 (enExample) | ||
| RU2022106770A (ru) | Модуляторы интегрированного сигнального пути стресса | |
| HRP20210252T1 (hr) | Heterociklički amidi kao inhibitori kinaze | |
| AU765473B2 (en) | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | |
| JP2013525433A5 (enExample) | ||
| WO2015101928A1 (en) | Fused thiophene and thiazole derivatives as ror gamma modulators | |
| CN114729044B (zh) | 毒蕈碱型乙酰胆碱m1受体拮抗剂 | |
| AU2019217320B2 (en) | Steroid derivative regulators, method for preparing the same, and uses thereof | |
| JP2019508407A5 (enExample) | ||
| AU2004215481A1 (en) | Pyrazolo(1,5-A)pyrimidine derivatives | |
| JP2009534407A5 (enExample) | ||
| JP2021501781A5 (enExample) | ||
| JP2017502088A5 (enExample) | ||
| JP2009534406A5 (enExample) | ||
| FI3215511T3 (fi) | Substituoituja pyratsolo(1,5-a)pyrimidiinejä ja niiden käyttö lääketieteellisten häiriöiden hoitamisessa | |
| JP2017538712A5 (enExample) | ||
| AU2019389017B2 (en) | Methods of treating disease with MAGL inhibitors | |
| CA3043612A1 (en) | Magl inhibitors | |
| HRP20230518T1 (hr) | Heteroarilfenoksibenzamidni opioidni ligandi kapa | |
| RS50443B (sr) | Derivati aminotiazola i njihova primena kao liganada crf receptora | |
| TW200635589A (en) | Therapeutic agents | |
| KR970042859A (ko) | 안료의 제조방법 |